Forget the biotech mega-round. Try the $200M-plus China 'ultra' on for size
Shanghai-based I-Mab Biopharma is helping to recalculate what the word “big’ means in biotech venture rounds. And it’s not $100 million.
The biotech has raised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
